News

Statement from the Canadian Generic Pharmaceutical Association Regarding Invitation for Canada to Join the Trans-Pacific Partnership (TPP) Negotiations

Toronto, June 19, 2012Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), today made the following statement regarding the formal invitation received by Canada to join the Trans-Pacific Partnership (TPP) negotiations:

“The Asia-Pacific Region is an important source of pharmaceutical inputs and other raw materials for Canadian-made generic medicines. The region is also an important export market for Canadian generic pharmaceutical manufacturers and presents enormous potential for export growth. Made-in-Canada generic drugs are currently exported to most TPP member countries, including Australia, Malaysia, New Zealand, Peru, Singapore, the United States and Vietnam.

As an industry that is heavily dependent on trade, generic pharmaceutical manufacturers support the Government of Canada’s efforts to eliminate tariff and non-tariff barriers, and expand trade opportunities for Canadian manufacturers. This includes participation in the Trans-Pacific Partnership negotiations.

CGPA’s support for Canada’s participation in the TPP negotiations does not represent support for all proposals that have or may be made in the context of the negotiations. Some pharmaceutical intellectual property provisions proposed in the negotiations would create significant delays in the ability of Canadian generic pharmaceutical companies to develop, manufacture and export new generic drugs to TPP member countries, which would greatly disadvantage generic pharmaceutical manufacturers in these countries in relation to those located in non-TPP countries.

Generic pharmaceutical associations from TPP member and applicant countries issued a joint position statement with respect to these proposals in May 2012. The generic pharmaceutical industry’s position is aimed at ensuring the sustainability of a vibrant generic pharmaceutical manufacturing presence in TPP member and applicant countries. Any agreement must also ensure that patients in TPP countries can continue to have timely access the cost-effective generic medicines they need to meet urgent care needs, and maintain or improve their quality of life.

This statement is available at:

www.canadiangenerics.ca/en/advocacy/docs/CGPA and generic industry position reTPP.pdf.

Canada’s intellectual property regime for pharmaceuticals exceeds international standards, and goes far beyond the provisions available in most TPP countries. As such, no new intellectual property provisions for pharmaceuticals should be required by Canada to conclude a Trans-Pacific Partnership agreement.

CGPA looks forward to working with the Government of Canada to ensure the final text of the Trans-Pacific Partnership will not create barriers for Canada’s generic pharmaceutical manufacturers in our ability to export to both TPP countries and other important markets around the globe.”

About the Canadian Generic Pharmaceutical Association
The Canadian Generic Pharmaceutical Association (CGPA) represents Canada’s generic pharmaceutical industry. The industry plays an important role in controlling health-care costs in Canada. Generic drugs are dispensed to more than 60 per cent of all prescriptions but account for only less than 24 percent of the $22-billion Canadians spend annually on prescription medicines.

For more information, please contact:

Jeff Connell
Vice President, Corporate Affairs
Canadian Generic Pharmaceutical Association (CGPA)
Tel: (416) 223-2333
Mobile: (647) 274-3379
Email: jeff@canadiangenerics.ca
Website: www.canadiangenerics.ca